ORKA
insider transactionsOruka Therapeutics, Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 30d
-55.9K
0 buy · 55.9K sell
Net value · 30d
-$3.9M
$0 in · $3.9M out
Sentiment · 30d
Net selling
0% buying · 100% selling
Open-market trades · 30d
13
0 buy · 55.9K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Chief Operating Officer
$41.8K
600 sh · $69.69
Own -0%
-
Sell·S
General Counsel
$51.1K
733 sh · $69.69
Own -2%
-
Sell·S
Chief Executive Officer
$120.5K
1.7K sh · $69.69
Own -0%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
3.5K sh
Own +2%
-
Sell·S
Chief Medical Officer · 10b5-1
$66.0K
947 sh · $69.69
Own -3%
-
Sell·S
Chief Medical Officer · 10b5-1
$21.2K
300 sh · $70.62
Own -1%
-
Sell·S
Chief Medical Officer · 10b5-1
$351.5K
5.1K sh · $69.42
Own -13%
-
Sell·S
Chief Medical Officer · 10b5-1
$111.9K
1.6K sh · $68.38
Own -4%
-
Exercise·M
Chief Medical Officer · 10b5-1
$27.3K
3.5K sh · $7.80
Own +9%
-
Exercise·M
Chief Medical Officer · 10b5-1
$23.9K
3.5K sh · $6.84
Own +10%
-
Sell·S
Arjun Agarwal KEY
Senior Vice President, Finance · 10b5-1
$27.5K
395 sh · $69.69
Own -2%
-
Sell·S
Director · 10b5-1
$882.2K
12.6K sh · $70.11
Own -25%
-
Exercise·M
Arjun Agarwal KEY
Senior Vice President, Finance · 10b5-1
$0
1.5K sh
Own +2%
-
Exercise·M
Arjun Agarwal KEY
Senior Vice President, Finance · 10b5-1
$0
8.0K sh
Own +8%
-
Sell·S
Arjun Agarwal KEY
Senior Vice President, Finance · 10b5-1
$229.3K
3.3K sh · $70.34
Own -16%
-
Sell·S
Arjun Agarwal KEY
Senior Vice President, Finance · 10b5-1
$303.2K
4.3K sh · $69.85
Own -17%
-
Sell·S
Arjun Agarwal KEY
Senior Vice President, Finance · 10b5-1
$127.0K
1.9K sh · $68.34
Own -7%
-
Exercise·M
Arjun Agarwal KEY
Senior Vice President, Finance · 10b5-1
$50.2K
1.5K sh · $34.39
Own +6%
-
Exercise·M
Arjun Agarwal KEY
Senior Vice President, Finance · 10b5-1
$100.0K
8.0K sh · $12.50
Own +46%
-
Sell·S
Director · 10b5-1
$1.6M
22.4K sh · $70.13
Own -30%
-
Grant·A
Director, 10% Owner
$0
34.8K sh
Own New
-
Grant·A
Director
$0
9.1K sh
Own New
-
Grant·A
Director
$0
9.1K sh
Own New
-
Grant·A
Director, 10% Owner
$0
9.1K sh
Own New
-
Grant·A
Director
$0
9.1K sh
Own New
-
Grant·A
Director
$0
9.1K sh
Own New
-
Grant·A
$0
8.0K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Laura Lee Sandler | Sell S | 600 | $41.8K |
| Jun 15, 2026 | Paul T Quinlan | Sell S | 733 | $51.1K |
| Jun 15, 2026 | Lawrence Otto Klein KEY | Sell S | 1.7K | $120.5K |
| Jun 15, 2026 | Joana Goncalves 10b5-1 | Exercise M | 3.5K | $0 |
| Jun 15, 2026 | Joana Goncalves 10b5-1 | Sell S | 947 | $66.0K |
| Jun 15, 2026 | Joana Goncalves 10b5-1 | Sell S | 300 | $21.2K |
| Jun 15, 2026 | Joana Goncalves 10b5-1 | Sell S | 5.1K | $351.5K |
| Jun 15, 2026 | Joana Goncalves 10b5-1 | Sell S | 1.6K | $111.9K |
| Jun 15, 2026 | Joana Goncalves 10b5-1 | Exercise M | 3.5K | $27.3K |
| Jun 15, 2026 | Joana Goncalves 10b5-1 | Exercise M | 3.5K | $23.9K |
| Jun 15, 2026 | Arjun Agarwal KEY 10b5-1 | Sell S | 395 | $27.5K |
| Jun 12, 2026 | Carl Dambkowski 10b5-1 | Sell S | 12.6K | $882.2K |
| Jun 12, 2026 | Arjun Agarwal KEY 10b5-1 | Exercise M | 1.5K | $0 |
| Jun 12, 2026 | Arjun Agarwal KEY 10b5-1 | Exercise M | 8.0K | $0 |
| Jun 12, 2026 | Arjun Agarwal KEY 10b5-1 | Sell S | 3.3K | $229.3K |
| Jun 12, 2026 | Arjun Agarwal KEY 10b5-1 | Sell S | 4.3K | $303.2K |
| Jun 12, 2026 | Arjun Agarwal KEY 10b5-1 | Sell S | 1.9K | $127.0K |
| Jun 12, 2026 | Arjun Agarwal KEY 10b5-1 | Exercise M | 1.5K | $50.2K |
| Jun 12, 2026 | Arjun Agarwal KEY 10b5-1 | Exercise M | 8.0K | $100.0K |
| Jun 11, 2026 | Carl Dambkowski 10b5-1 | Sell S | 22.4K | $1.6M |
| Jun 9, 2026 | Fairmount Funds Management LLC / Fairmount Healthcare Fund II L.P. / Fairmount Healthcare Co-Invest IV L.P. / Tomas Kiselak / Peter Evan Harwin | Grant A | 34.8K | $0 |
| Jun 2, 2026 | Christopher Nathan Martin | Grant A | 9.1K | $0 |
| Jun 2, 2026 | Samarth Kulkarni | Grant A | 9.1K | $0 |
| Jun 2, 2026 | Fairmount Funds Management LLC / Fairmount Healthcare Fund II L.P. / Fairmount Healthcare Co-Invest III L.P. / Peter Evan Harwin / Tomas Kiselak | Grant A | 9.1K | $0 |
| Jun 2, 2026 | Carl Dambkowski | Grant A | 9.1K | $0 |
| Jun 2, 2026 | Kristine M Ball | Grant A | 9.1K | $0 |
| May 27, 2026 | Fairmount Funds Management LLC / Tomas Kiselak / Fairmount Healthcare Fund II L.P. | Grant A | 8.0K | $0 |
About ORKA insider trading
This page tracks insider transactions for Oruka Therapeutics, Inc. (ORKA) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.